



# RHEUMATOLOGY REFERRAL FORM A-C



## Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

### INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

## Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Actemra (tocilizumab)	<input type="checkbox"/> 162mg/0.9mL Prefilled Syringe	<input type="checkbox"/> Inject 162mg subcutaneously every other week.	<input type="checkbox"/> 2 syringes/pens <input type="checkbox"/> 4 syringes/pens	
	<input type="checkbox"/> 162mg/09mL Actemra ACTPen	<input type="checkbox"/> Inject 162mg subcutaneously once a week.	<input type="checkbox"/> _____ syringes/pens	
<input type="checkbox"/> Cimzia (certolizumab)	<input type="checkbox"/> Starter Kit 200mg/mL Prefilled Syringe	<input type="checkbox"/> Loading Dose: Inject 400mg (2 syringes) subcutaneously at weeks 0, 2 and 4.	1 kit (6 syringes)	
	<input type="checkbox"/> 200mg/mL Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 400mg (2 syringes) subcutaneously every 4 weeks. <input type="checkbox"/> Maintenance Dose: Inject 200mg (1 syringe) subcutaneously every 2 weeks.	<input type="checkbox"/> 2 syringes <input type="checkbox"/> 6 syringes	
<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> 150mg Sensoready Pen	<input type="checkbox"/> Loading Dose: Inject 150mg subcutaneously once weekly at weeks 0, 1, 2, 3, and 4. <input type="checkbox"/> Loading Dose: Inject 300mg (2 injections of 150mg) subcutaneously once weekly at weeks 0, 1, 2, 3, and 4.	<input type="checkbox"/> 4 syringes/pens <input type="checkbox"/> 8 syringes/pens	
	<input type="checkbox"/> 150mg Prefilled Syringe	<input type="checkbox"/> Maintenance dose: Starting at week 4, inject 150mg subcutaneously every 4 weeks. <input type="checkbox"/> Maintenance dose: Starting at week 4, inject 300mg (2 injections of 150mg) subcutaneously every 4 weeks.	<input type="checkbox"/> 1 syringe/pen <input type="checkbox"/> 2 syringes/pens <input type="checkbox"/> _____ syringes/pens	

**Treatment History:**  New to Therapy  Continuation of Therapy

Hepatitis B Screening Results:  HBsAg: \_\_\_\_\_  Anti-HBs: \_\_\_\_\_  Anti-HBc: \_\_\_\_\_

If applicable, has treatment been initiated?  Yes  No

Tuberculosis Assessment Date: \_\_\_\_\_  Negative  Active TB  Latent TB  History of active or latent TB

If history of active or latent TB: \_\_\_\_\_ Adequate treatment is confirmed:  Yes  No

History of Irritable Bowel Disease:  Yes  No

## Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

## Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

*Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.*

It's as simple as caring.



# RHEUMATOLOGY REFERRAL FORM D-H



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 50mg/mL Sureclick Auto-injector <input type="checkbox"/> 50mg/mL Prefilled Syringe <input type="checkbox"/> 50mg/mL Enbrel Mini	<input type="checkbox"/> Inject 50mg subcutaneously once a week.	4 syringes/pens	
	<input type="checkbox"/> 25mg/0.5mL Prefilled Syringe <input type="checkbox"/> 25mg Vial	<input type="checkbox"/> Inject 25mg subcutaneously twice a week.	8 syringes/vials	
<input type="checkbox"/> Humira (adalimumab) Patient weight: _____ kg	10kg to < 15kg <input type="checkbox"/> 10mg/0.1 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 10mg/0.2 mL Prefilled Syringe	<input type="checkbox"/> Inject 10mg subcutaneously every OTHER week.		
	15kg to < 30kg <input type="checkbox"/> 20mg/0.2 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 20mg/0.4 mL Prefilled Syringe	<input type="checkbox"/> Inject 20mg subcutaneously every OTHER week.	<input type="checkbox"/> 2 syringes/pens <input type="checkbox"/> 4 syringes/pens	
	≥ 30kg <input type="checkbox"/> 40mg/0.4 mL Citrate-free Pen <input type="checkbox"/> 40mg/0.8 mL Pen <input type="checkbox"/> 40mg/0.4 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 40mg/0.8 mL Prefilled Syringe	<input type="checkbox"/> Inject 40mg subcutaneously every OTHER week. <input type="checkbox"/> Inject 40mg subcutaneously every week.		

### Treatment History: New to Therapy Continuation of Therapy

Hepatitis B Screening Results:  HBsAg: \_\_\_\_\_  Anti-HBs: \_\_\_\_\_  Anti-HBc: \_\_\_\_\_

If applicable, has treatment been initiated?  Yes  No

Tuberculosis Assessment Date: \_\_\_\_\_  Negative  Active TB  Latent TB  History of active or latent TB

If history of active or latent TB: \_\_\_\_\_ Adequate treatment is confirmed:  Yes  No

History of Irritable Bowel Disease:  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 \_\_\_\_\_ Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

*Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.*

It's as simple as caring.



# RHEUMATOLOGY REFERRAL FORM I-N



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Kevzara®	<input type="checkbox"/> 150mg/1.14mL Pen <input type="checkbox"/> 150mg/1.14mL Prefilled Syringe <input type="checkbox"/> 200mg/1.14mL Pen <input type="checkbox"/> 200mg/1.14mL Prefilled Syringe	<input type="checkbox"/> Inject 200mg subcutaneously every two weeks. <input type="checkbox"/> Inject 150mg subcutaneously every two weeks.	2 syringes/pens	
<input type="checkbox"/> Kineret (anakinra)	100mg/0.67mL Prefilled Syringe	Inject 100mg subcutaneously every 24 hours.	28 syringes	

Treatment History:  New to Therapy  Continuation of Therapy

Hepatitis B Screening Results:  HBsAg: \_\_\_\_\_  Anti-HBs: \_\_\_\_\_  Anti-HBc: \_\_\_\_\_  
 If applicable, has treatment been initiated?  Yes  No  
 Tuberculosis Assessment Date: \_\_\_\_\_  Negative  Active TB  Latent TB  History of active or latent TB  
 If history of active or latent TB: \_\_\_\_\_ Adequate treatment is confirmed:  Yes  No  
 History of Irritable Bowel Disease:  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted  Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.

# RHEUMATOLOGY REFERRAL FORM O



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Olumiant®	2mg Tablets	Take one tablet by mouth once daily.	30 tablets	
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 250mg Vial (IV use only)	<input type="checkbox"/> Loading Dose: Inject _____mg via intravenous infusion at 0, 2 and 4 weeks.	3 vials	
	<input type="checkbox"/> Inject _____mg via intravenous infusion every 4 weeks.		____ vials	
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 125mg/mL Prefilled Syringe	<input type="checkbox"/> Adults and children ≥ 50 kg: Inject 125mg subcutaneously once weekly.	4 syringes/ autoinjectors	
	<input type="checkbox"/> 125mg/mL Auto-injector			
<input type="checkbox"/> Otrexup (methotrexate)	<input type="checkbox"/> 7.5mg/0.4mL Auto-injector <input type="checkbox"/> 10mg/0.4mL Auto-injector <input type="checkbox"/> 12.5mg/0.4mL Auto-injector <input type="checkbox"/> 15mg/0.4mL Auto-injector <input type="checkbox"/> 17.5mg/0.4mL Auto-injector <input type="checkbox"/> 20mg/0.4mL Auto-injector <input type="checkbox"/> 22.5mg/0.4mL Auto-injector <input type="checkbox"/> 25mg/0.4mL Auto-injector	Inject one autoinjector subcutaneously once weekly.	4 autoinjectors	

## Treatment History: New to Therapy Continuation of Therapy

Hepatitis B Screening Results:  HBsAg: \_\_\_\_\_  Anti-HBs: \_\_\_\_\_  Anti-HBc: \_\_\_\_\_  
 If applicable, has treatment been initiated?  Yes  No  
 Tuberculosis Assessment Date:  Negative  Active TB  Latent TB  History of active or latent TB  
 If history of active or latent TB: \_\_\_\_\_ Adequate treatment is confirmed:  Yes  No  
 History of Irritable Bowel Disease:  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

*Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.*

It's as simple as caring.



# RHEUMATOLOGY REFERRAL FORM P-R



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Rasuvo (methotrexate)	<input type="checkbox"/> 7.5mg/0.15 Auto-injector <input type="checkbox"/> 10mg/0.2mL Auto-injector <input type="checkbox"/> 12.5mg/0.25mL Auto-injector <input type="checkbox"/> 15mg/0.3mL Auto-injector <input type="checkbox"/> 17.5mg/0.35mL Auto-injector <input type="checkbox"/> 20mg/0.4mL Auto-injector <input type="checkbox"/> 22.5 mg/0.45mL Auto-injector <input type="checkbox"/> 25mg/0.5mL Auto-injector <input type="checkbox"/> 27.5mg/0.55mL Auto-injector <input type="checkbox"/> 30mg/0.6mL Auto-injector	Inject one autoinjector subcutaneously once weekly.	4 autoinjectors	
<input type="checkbox"/> Remicade (infliximab)	100mg Vial	<input type="checkbox"/> Loading Dose: Administer _____mg (at _____ mg/kg) intravenously at 0, 2 and 6 weeks.	_____vials	
<input type="checkbox"/> Inflectra (infliximab-dyyb) Patient weight: _____ kg		<input type="checkbox"/> Maintenance Dose: Administer _____mg (at _____mg/kg) intravenously every _____weeks.	_____vials	

## Treatment History: New to Therapy Continuation of Therapy

Hepatitis B Screening Results:  HBsAg: \_\_\_\_\_  Anti-HBs: \_\_\_\_\_  Anti-HBc: \_\_\_\_\_  
 If applicable, has treatment been initiated?  Yes  No  
 Tuberculosis Assessment Date: \_\_\_\_\_  Negative  Active TB  Latent TB  History of active or latent TB  
 If history of active or latent TB: \_\_\_\_\_ Adequate treatment is confirmed:  Yes  No  
 History of Irritable Bowel Disease:  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 \_\_\_\_\_ Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

*Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.*

It's as simple as caring.

# RHEUMATOLOGY REFERRAL FORM S-Z



Patient Information

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex:  M  F  
 Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 ICD-10 Diagnosis Code: \_\_\_\_\_ Diagnosis: \_\_\_\_\_  
 Allergies (please note reaction): \_\_\_\_\_  Latex  
 Current Medications: (list here or attach a medication list): \_\_\_\_\_  
 Comorbidities: (list here or attach a list): \_\_\_\_\_

## INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50mg/0.5mL SmartJect Auto-injector <input type="checkbox"/> 50mg/0.5mL Prefilled Syringe	Inject 50mg subcutaneously once monthly.	<input type="checkbox"/> 1 syringe/pen <input type="checkbox"/> 3 syringes/pens	
<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> 80mg/mL Auto-injector <input type="checkbox"/> 80mg/mL Prefilled Syringe	<input type="checkbox"/> Inject 160mg subcutaneously at weeks 2, 4, 6, 8, 10 and 12; then inject 80mg subcutaneously every 4 weeks.	<input type="checkbox"/> 4 syringes/pens	2
		<input type="checkbox"/> Inject 160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks.	<input type="checkbox"/> 1 syringe/pen <input type="checkbox"/> 2 syringes/pens	
		<input type="checkbox"/> Inject 80mg subcutaneously every 4 weeks.		
<input type="checkbox"/> Xeljanz (tofacitinib)	<input type="checkbox"/> 5mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth twice daily.	60 tablets	
		<input type="checkbox"/> Take 1 tablet by mouth once a day (renal/hepatic impairment).	30 tablets	
<input type="checkbox"/> Xeljanz XR (tofacitinib)	<input type="checkbox"/> 11mg XR Tablet	Take 1 tablet by mouth once daily.	30 tablets	
Other Medication Name:				

Treatment History:  New to Therapy  Continuation of Therapy

Hepatitis B Screening Results:  HBsAg: \_\_\_\_\_  Anti-HBs: \_\_\_\_\_  Anti-HBc: \_\_\_\_\_

If applicable, has treatment been initiated?  Yes  No

Tuberculosis Assessment Date: \_\_\_\_\_  Negative  Active TB  Latent TB  History of active or latent TB

If history of active or latent TB: \_\_\_\_\_ Adequate treatment is confirmed:  Yes  No

History of Irritable Bowel Disease:  Yes  No

Prescriber Information

Prescriber Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ DEA #: \_\_\_\_\_ NPI: \_\_\_\_\_  
 Additional Contact Person Name: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_ Email Address: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_  
 Product Substitution Permitted \_\_\_\_\_ Dispensed as Written \_\_\_\_\_ Date \_\_\_\_\_

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Delivery Information

Ship to Patient  Ship to Prescriber/Clinic  Pick up at Albertsons Companies Pharmacy Date Medication Needed: \_\_\_\_\_

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.

It's as simple as caring.